Esteban Dominguez Cerezo, MS,  Science Writer—

A 50-year-old woman in the U.S. developed secondary cold agglutinin disease (CAD), a rare form of autoimmune anemia, as a complication of advanced breast cancer, a case study detailed. The researchers acknowledged that CAD “is rarely secondary to solid tumors,” as are typically seen in breast cancer. But they…

Recordati agreed to acquire the global rights to Enjaymo (sutimlimab), the only approved targeted therapy for cold agglutinin disease (CAD), from Sanofi. “With a strong clinical profile and as the only product approved for the treatment of CAD, Enjaymo addresses a serious unmet medical need for patients…